These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33188147)

  • 21. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
    Cai Z; Chen W; Zhang J; Li H
    Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer.
    Lv S; Song Q; Chen G; Cheng E; Chen W; Cole R; Wu Z; Pascal LE; Wang K; Wipf P; Nelson JB; Wei Q; Huang W; Wang Z
    J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
    McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
    Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
    Shen T; Wang W; Zhou W; Coleman I; Cai Q; Dong B; Ittmann MM; Creighton CJ; Bian Y; Meng Y; Rowley DR; Nelson PS; Moore DD; Yang F
    J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
    Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
    Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.
    Gowda PS; Deng JD; Mishra S; Bandyopadhyay A; Liang S; Lin S; Mahalingam D; Sun LZ
    Mol Cancer Res; 2013 Nov; 11(11):1448-61. PubMed ID: 23989930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches.
    Labrecque MP; Alumkal JJ; Coleman IM; Nelson PS; Morrissey C
    Endocr Relat Cancer; 2021 Jul; 28(8):T51-T66. PubMed ID: 33792558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The concept and mechanisms of castration-resistant prostate cancer].
    Naito S; Shiota M
    Nihon Rinsho; 2014 Dec; 72(12):2090-4. PubMed ID: 25518339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
    Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
    Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52.
    Joshi JB; Patel D; Morton DJ; Sharma P; Zou J; Hewa Bostanthirige D; Gorantla Y; Nagappan P; Komaragiri SK; Sivils JC; Xie H; Palaniappan R; Wang G; Cox MB; Chaudhary J
    Mol Oncol; 2017 Apr; 11(4):337-357. PubMed ID: 28252832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Pilling A; Kim SH; Hwang C
    Prostate; 2022 Feb; 82(2):182-192. PubMed ID: 34672379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
    Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
    J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).
    De Vitis M; Berardinelli F; Sgura A
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
    Peacock SO; Fahrenholtz CD; Burnstein KL
    Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
    Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
    Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
    Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
    Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen receptor-induced integrin α6β1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer.
    Nollet EA; Cardo-Vila M; Ganguly SS; Tran JD; Schulz VV; Cress A; Corey E; Miranti CK
    Oncogene; 2020 Jul; 39(31):5390-5404. PubMed ID: 32565538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.
    Groner AC; Cato L; de Tribolet-Hardy J; Bernasocchi T; Janouskova H; Melchers D; Houtman R; Cato ACB; Tschopp P; Gu L; Corsinotti A; Zhong Q; Fankhauser C; Fritz C; Poyet C; Wagner U; Guo T; Aebersold R; Garraway LA; Wild PJ; Theurillat JP; Brown M
    Cancer Cell; 2016 Jun; 29(6):846-858. PubMed ID: 27238081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.